Daratumumab SC

Phase 3Monoclonal antibody

Johnson & Johnson

Daratumumab SC is one of 60 biologic programs targeting Lymphoma, Primary Effusion. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Lymphoma, Primary EffusionRecruiting

Multiple Myeloma, Newly DiagnosedRecruiting

AmyloidosisActive, not recruiting

Multiple MyelomaCompleted

DaratumumabRecruiting

Lymphoma, Primary EffusionPhase 2

Recruiting

Multiple Myeloma, Newly DiagnosedPhase 3

Recruiting

AmyloidosisPhase 2

Active, not recruiting

Multiple MyelomaPhase 3

Completed

DaratumumabPhase 2

Recruiting

Competition

Competitive Landscape

282 competitors in Multiple Myeloma

#DrugCompanyPhaseTrials

Empliciti

Bristol-Myers Squibb

Phase 3

45 2

Belamaf

GSK

Phase 3

39 3

Fludara

Sanofi

Phase 3

47 4

TALVEY

Johnson & Johnson

Phase 3

24 5

Venclexta

AbbVie

Phase 3

17 6

Keytruda

Merck & Co.

Phase 3

17 7

Sarclisa

AAzienda U.S.L. 1 di Massa e Carrara

Phase 3

42 8

Azatiq

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

23 9

Treanda

AAzurity Pharmaceuticals

Vepesid

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 1Active, not recruiting

Multiple Myeloma

NCT05050097

Q4 2027

Phase 2Active, not recruiting

Multiple Myeloma

NCT04302324

Q1 2028

Phase 2Active, not recruiting

Amyloidosis

NCT04270175

Q4 2029

Phase 2Recruiting

Daratumumab

NCT06100237

Clinical

Trials by Indication[1]

Multiple Myeloma5 trials

Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT02252172·737 enrolled

A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT02195479·706 enrolled

INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Relapsed or Refractory Multiple Myeloma

Terminated· Incyte logo

Incyte·Phase 1/2·NCT03837509·15 enrolled

Show 2 more trials

A Phase II Study of Daratumumab, Clarithromycin, Pomalidomide And Dexamethasone (D-ClaPd) In Multiple Myeloma Patients Previously Exposed to Daratumumab

Active, not recruiting·WWeill Medical College of Cornell University·Phase 2·NCT04302324·9 enrolled

A Multi-arm Phase 1b Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma

Active, not recruiting· Johnson & Johnson logo

Johnson & Johnson·Phase 1·NCT05050097·166 enrolled

Heart Transplantation1 trial

Daratumumab-SC for Highly Sensitized Patients Awaiting Heart Transplantation

Completed·RRonald Witteles·Phase 1·NCT04610320·8 enrolled

Daratumumab1 trial

Teclistamab in Combination With Daratumumab for High-Risk Smoldering Myeloma: A Clinical and Correlative Phase 2 Immuno-Oncology Study (the REVIVE Study)

Recruiting·—·Phase 2·NCT06100237·50 enrolled

Amyloidosis1 trial

Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab

Active, not recruiting·WWeill Medical College of Cornell University·Phase 2·NCT04270175·15 enrolled

Lymphoma, Primary Effusion1 trial

A Phase II Study of Daratumumab for Relapsed/Refractory Primary Effusion Lymphoma, Plasmablastic Lymphoma, and Multicentric Castleman Disease

Recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT05907759·28 enrolled

1 more indication

Multiple Myeloma, Newly Diagnosed1 trial

A Phase 3, Open-label, Controlled, Randomized Study of Newly Diagnosed Multiple Myeloma Treatment, Designed to Evaluate the Efficacy and Safety of the Elranatamab-lenalidomide Combination as a Replacement for Chemotherapy Followed by Autologous Stem Cell Transplant in the Consolidation Phase, and to Compare Elranatamab With Standard of Care in the Maintenance Phase

Recruiting·IIntergroupe Francophone du Myelome·Phase 3·NCT06918002·824 enrolled

Sources

References

[1]
ClinicalTrials.gov — 10 trial records for Daratumumab SC. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Daratumumab SC compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Daratumumab SC. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Johnson & Johnson company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 3[1]
Company: Johnson & Johnson

Daratumumab SC

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q4 2027

Q1 2028

Q4 2029

Trials by Indication[1]

Multiple Myeloma5 trials

Heart Transplantation1 trial

Daratumumab1 trial

Amyloidosis1 trial

Lymphoma, Primary Effusion1 trial

Multiple Myeloma, Newly Diagnosed1 trial

References

Drug Info

Quick Facts

Related News